Hidenori Mikamiyama

This inventor holds 14 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Shionogi Company Limited, Purdue Pharma L.p.. Active years: 2006-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hidenori Mikamiyama. Retrieved from https://idiyas.com/inventor/hidenori-mikamiyama

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14 (Patent Applications = 8)

% Patents Active = 71.4

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 8)

Average Co-Inventor Count = 3.7

ph-index = 5

Forward Citations = 92(Granted Patents)

Location History:

Toyonaka, JP (2015)
Osaka, JP (2006 - 2019)

Company Filing History:

13 out of 1,001

Shionogi Company Limited

where one patent can have more than one assignee

Years Active: 2006-2019

Loading Chart...

Areas of Expertise:

Carbamoyl Derivatives

Polycyclic Compounds

Benzenesulfonamide

Acrylamide Compounds

Oxyimino Compounds

Heterocycle Derivatives

Heteroaryl Compounds

HIV Integrase Inhibitors

Tetrahydropyridinyl Compounds

Dihydropyrrolyl Compounds

Nitrogen-Containing Compounds

Hydroxypyrimidinone Derivatives

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10202379 - Substituted polycyclic carbamoyl pyridone derivative prodrug (2019-02-12),

2. 9815835 - Substituted polycyclic carbamolypyridone derivative (2017-11-14),

3. 9469638 - Substituted polycyclic carbamoylpyridone derivative (2016-10-18),

4. 8987441 - Substituted polycyclic carbamoyl pyridone derivative prodrug (2015-03-24),

5. 8937181 - Benzenesulfonamide compounds and the use thereof (2015-01-20),

6. 8927710 - Substituted polycyclic carbamoylpyridone derivative (2015-01-06),

7. 8895551 - Acrylamide compounds and the use thereof (2014-11-25),

8. 8563732 - Oxyimino compounds and the use thereof (2013-10-22),

9. 8518934 - Oxycarbamoyl compounds and the use thereof (2013-08-27),

10. 8324249 - Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof (2012-12-04),

11. 7935706 - Nitrogen-containing heterocycle derivatives substituted with cyclic group (2011-05-03),

12. 7759372 - Nitrogen-containing heteroaryl compounds having inhibitory activity against HIV integrase (2010-07-20),

13. 7745453 - Hydroxypyrimidinone derivatives having inhibitory activity against HIV integrase (2010-06-29),

14. 7148237 - Nitrogen-containing heteroaryl compounds having HIV integrase inhibitory activity (2006-12-12),

Title: The Innovative Journey of Hidenori Mikamiyama

Introduction

Hidenori Mikamiyama, an accomplished inventor based in Osaka, Japan, has made significant contributions to the field of antiviral compounds with a particular focus on influenza viruses. With a remarkable portfolio of 14 patents, he has dedicated his career to the development of innovative solutions for pressing health challenges.

Latest Patents

Among his latest inventions, Hidenori has introduced the "Substituted polycyclic carbamoyl pyridone derivative prodrug". This groundbreaking compound exhibits antiviral effects, especially demonstrating growth inhibitory activity on influenza viruses. A preferred example from his patents is the substituted 3-hydroxy-4-pyridone derivative prodrug that possesses cap-dependent endonuclease inhibitory activity. Additionally, he has developed a similar invention, the "Substituted polycyclic carbamolypyridone derivative," which also targets influenza viruses, specifically providing enhanced activity through substituted 3-hydroxy-4-pyridone derivatives with cap-dependent endonuclease inhibition.

Career Highlights

Hidenori Mikamiyama's career includes pivotal roles at prominent pharmaceutical companies. He worked with Shionogi & Company Limited and Purdue Pharma L.P., where he collaborated with many exceptional professionals to advance his research on antiviral compounds. His work reflects a commitment to scientific excellence and innovation, propelling forward the treatment options available for viral infections.

Collaborations

Throughout his career, Hidenori has had the opportunity to collaborate with esteemed colleagues, including Yoshiyuki Taoda and Toshiyuki Akiyama. These professional relationships have fostered many fruitful discussions and have likely contributed to the advancement of his innovative ideas and patent developments.

Conclusion

Hidenori Mikamiyama stands out as a key figure in the field of antiviral research, particularly in combating influenza viruses through novel chemical compounds. His impressive array of patents and collaborations with leading companies and researchers showcases his dedication to improving global health outcomes through innovation. His ongoing contributions continue to inspire and drive progress in the pharmaceutical industry.

Profile summary based on public USPTO records.